Journal-based CME Course: Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis

Activity ID

8877

Expires

October 7, 2024

Format Type

Journal-based

CME Credit

Fee

$30

CME Provider: JAMA Neurology

Description of CME Course

This cohort study investigates the humoral response to 2 SARS-CoV-2 messenger RNA vaccines in patients with multiple sclerosis treated with fingolimod and ocrelizumab.

Disclaimers

1. This activity is accredited by the American Medical Association.
2. This activity is free to AMA members.

ABMS Member Board Approvals by Type

ABMS Lifelong Learning CME Activity

Allergy and Immunology

Anesthesiology

Colon and Rectal Surgery

Family Medicine

Medical Genetics and Genomics

Nuclear Medicine

Ophthalmology

Orthopaedic Surgery

Pathology

Physical Medicine and Rehabilitation

Plastic Surgery

Preventive Medicine

Psychiatry and Neurology

Radiology

Thoracic Surgery

Urology

More Information

Commercial Support?

NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

General Information on CME Activity

Educational Objectives

To identify the key insights or developments described in this article

Keywords

Demyelinating Disorders, Multiple Sclerosis, Neurology, Vaccination, Coronavirus (COVID-19)

Competencies

Medical Knowledge

CME Credit Type

AMA PRA Category 1 Credit

DOI

10.1001/jamaneurol.2021.3609